Globus Medical (NYSE:GMED) Updates FY 2025 Earnings Guidance

Globus Medical (NYSE:GMED) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 3.400-3.500 for the period. The company issued revenue guidance of $2.7 billion-$2.7 billion, compared to the consensus revenue estimate of $2.7 billion.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Canaccord Genuity Group boosted their target price on Globus Medical from $92.00 to $101.00 and gave the stock a “buy” rating in a report on Friday, January 10th. StockNews.com upgraded Globus Medical from a “hold” rating to a “buy” rating in a report on Friday, February 14th. Barclays upped their price target on Globus Medical from $100.00 to $103.00 and gave the stock an “overweight” rating in a report on Monday. BTIG Research upped their price target on Globus Medical from $87.00 to $91.00 and gave the stock a “buy” rating in a report on Thursday, December 12th. Finally, Truist Financial upped their price target on Globus Medical from $85.00 to $90.00 and gave the stock a “hold” rating in a report on Wednesday, December 18th. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, Globus Medical presently has an average rating of “Moderate Buy” and a consensus price target of $97.82.

Globus Medical Price Performance

Shares of GMED stock traded down $1.46 during trading hours on Thursday, hitting $78.55. 960,805 shares of the company’s stock were exchanged, compared to its average volume of 1,318,071. The stock’s 50-day moving average is $86.57 and its 200-day moving average is $79.25. The stock has a market cap of $10.70 billion, a price-to-earnings ratio of 104.74, a price-to-earnings-growth ratio of 1.61 and a beta of 1.19. Globus Medical has a 52 week low of $49.33 and a 52 week high of $94.93.

Globus Medical (NYSE:GMED) last announced its earnings results on Thursday, February 20th. The medical device company reported $0.84 EPS for the quarter, topping the consensus estimate of $0.74 by $0.10. The company had revenue of $657.29 million for the quarter, compared to analysts’ expectations of $646.19 million. Globus Medical had a return on equity of 10.83% and a net margin of 4.09%. Equities research analysts forecast that Globus Medical will post 3.44 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Kelly Huller sold 2,500 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $87.00, for a total transaction of $217,500.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Keith W. Pfeil sold 14,167 shares of the firm’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $88.29, for a total value of $1,250,804.43. The disclosure for this sale can be found here. 18.54% of the stock is currently owned by insiders.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.